ImmunAdd Inc.

#ImmunAdd wishes you a merry Christmas~ We wish you a merry Christmas and a happy new year. This busy year is coming to an end. We have to thank you for your support and collaboration. Wishing you good luck, good health, and lots of cheer as well. May the New Year bring you prosperity and joy! #Innovation_for_better_health #we_are_ImmunAdd

We attend the ISV annual congress 2024 in Seoul, South Korea and will speak entitled “ Novel fully synthetic saponin-based vaccine adjuvant for protein based Vaccines” in Oct. 21. Please join our talk and discuss how we can work together. #ISV_2024 #ImmunAdd

Follow-up Photos for #2024_BIO_Asia_Taiwan #Taiwan_BIO_Awards_Successful_Stories #Taiwan_BIO_Awards_Ceremony #Taiwan_BIO_Awards_group_photo

ImmunAdd won the Startup of the Year at the 2024 Taiwan BIO Awards ImmunAdd won the Startup of the Year at the 2024 Taiwan BIO Awards and the Awards ceremony will be held on July 25th. ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. ImmunAdd was founded in 2022 but has put efforts into researching synthetic saponin for nearly a decade. ImmunAdd’s first product, IA-05, is designed as a vaccine adjuvant, which could be incorporated into a vaccine product to improve efficacy and extend the protection period. IA-05 exhibits comparable adjuvant activity to QS-21 and is safer when used in combination with various vaccines. “The development of IA-05 and its proven effect marks a major milestone in the field of vaccine adjuvants” Dr. Pi-Hui Liang, CEO said. “We have developed a total synthesis method for saponin adjuvants that not only meets the growing demand but also protects the forest and ensures the long-term sustainable supply of the adjuvant.” ImmunAdd is now seeking partnerships to co-develop innovative and practical pharmaceutics for better health. #Innovation_for_better_health We are #ImmunAdd.

We are thrilled to announce that our CEO - Pi-Hui Liang will present in the United States-Japan Cooperative Medical Sciences Program (USJCMSP) for the update progress of our sustainable saponin-based adjuvant. Every year, the USJCMP holds a conference to bring together investigators from the United States, Japan, and other countries to discuss various topics in infectious diseases, cancer, and immunology, and to promote possible opportunities for collaboration. The title for the upcoming annual meeting is “The 2024 International Conference on Emerging Infectious Diseases (EID).” This meeting will be held in Incheon, South Korea and will be held from March 5th through 8th. #USJCMSP2024: https://lnkd.in/gb_2bVXQ